GT
KYMR icon

Glenmede Trust’s Kymera Therapeutics KYMR Stock Holding History

Glenmede Trust’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$565K Buy
6,779
+235
+4% +$18.6K ﹤0.01% 921
2025
Q4 		$509K Buy
+6,544
New +$442K ﹤0.01% 938
2021
Q3 		– Sell
-5,000
Closed -$242K – 1316
2021
Q2 		$242K Buy
+5,000
New +$217K ﹤0.01% 1090

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Glenmede Trust's KYMR Position: Q1 2026 in Review

Glenmede Trust increased its Kymera Therapeutics (KYMR) stake by 3.6% in Q1 2026, buying an estimated $18.6K and bringing the position to 6,779 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Glenmede Trust first reported a position in KYMR in Q2 2021 and has held it in 3 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Glenmede Trust held 6,779 shares of Kymera Therapeutics worth $565K as of Q1 2026.
  • Glenmede Trust bought 235 Kymera Therapeutics shares in Q1 2026, an estimated $18.6K.
  • Kymera Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #921 holding.
  • Glenmede Trust first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.